Based on observational data, a 2011 report highlighted an increased risk of pancreatitis and pancreatic cancer in patients using incretin therapy (Elashoff et al., 2011), prompting a warning from the Food and Drug Administration (FDA) regarding the pancreatic safety of GLP-1 RAs (Administration, 2013). This evidence concerns the gene GCG and pancreatitis.